DiamiR Announces Oral Presentation at 2016 Alzheimer's Association International Conference

MONMOUTH JUNCTION, NJ --(Marketwired - July 21, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today that the company's Chief Executive Officer, Dr. Kira Sheinerman, will present at the Alzheimer's Association International Conference (AAIC) taking place in Toronto, Canada, July 24-28.

Title: Circulating Brain-Enriched microRNAs As Biomarkers for Early Detection and Differential Diagnosis of Alzheimer's Disease
Session: Biomarkers: Novel Biomarkers
Date/Time: Thursday, July 28, 2016, 1:00 PM ET
Location: Metro Toronto Convention Centre, 105

About AAIC

The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the reporting and discussion of groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders. As a part of the Association's research program, AAIC serves as a catalyst for generating new knowledge about Alzheimer's and fostering a vital and collegial research community.

About DiamiR

DiamiR, a wholly-owned subsidiary of DiamiR Biosciences Corp., is a privately held molecular diagnostics company focused on developing minimally invasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer's and Parkinson's diseases, and other conditions. The proprietary technology is based on quantitative analysis of organ-enriched microRNA signatures in plasma and is being developed for screening, patient stratification as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic and clinical centers, disease foundations and life sciences companies. For more information, please visit the company's website at www.diamirbio.com.

Please Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; the results of studies of our product candidates conducted by others; our ability to obtain future funding on acceptable terms; our ability to obtain regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights; and innovation by our competitors.